Introduction
noradrenaline outflow (Figure 1) . Interestingly, the AT2 receptor blockers PD123319 (1 mM ) (Figure 1 ) Congestive heart failure is characterized by overactivity and CGP42112A (1 mM ) (data not shown) reduced of the sympathetic nervous system and of the renin-anthe Ang II-induced increase of noradrenaline by~50% giotensin system. When plasma noradrenaline is elevover the whole concentration range of Ang II in atria. ated, patient survival is extremely poor [1] due to the A combination of EXP3174 (0.01 mmol/l ) and high incidence of progressive heart failure and sudden PD123319 (1 mmol/l ) did not inhibit noradrenaline cardiac death. There is substantial evidence to suggest release to a greater extent than EXP3174 alone. An that angiotensin (Ang) II may in part be responsible inhibition with PD123319 was not observed in renal for an increase in noradrenaline release in this clinical cortex ( Figure 1 ). Furthermore, acetylcholine release setting [2] . Thus, activation of facilitatory Ang II was increased by Ang II (0.01-1 mM ) in atria. receptors, located presynaptically on sympathetic nerve endings, leads to enhanced release of noradrenaline per nerve impulse. Chronic renal failure is associated
Discussion
with increased sympathetic tone [3] , and sudden cardiac death is the most common cause of death in endstage renal failure. Angiotensin-converting enzyme Sympathetic nerve endings in human heart and kidney (ACE) inhibitor therapy is standard in chronic heart possess Ang II receptors of the AT1 subtype which, and kidney failure. Today, Ang II (AT1) receptor when activated by Ang II, mediate an increase of blockers as a new class of drugs are available. The noradrenaline outflow. This facilitatory effect of Ang ELITE study showed that heart failure patients treated II is prevented by EXP3174, the in vitro active form with an Ang II receptor blocker had a lower mortality of the AT1 receptor blocker losartan. Furthermore, than those treated with an ACE inhibitor [4] . Now we EXP3174, but not the ACE inhibitor captopril, totally investigate the relative contribution of AT1 and AT2 blocked Ang I-induced noradrenaline release in human receptors to Ang II modulation of cardiac and renal atria [7] and kidney [8] . Therefore, it was suggested transmitter release.
that even in the presence of ACE inhibition, substantial amounts of Ang II can be formed from Ang I locally in the heart by enzymes other than ACE to enhance However, especially in the heart, the situation may The effects of Ang II, the AT1 receptor blocker, EXP3174, be far more complex. We found that AT2 receptor and the AT2 receptor blockers, PD123319 and CGP42112A, blockers attenuated the facilitatory effect of Ang II on were tested at different concentrations. noradrenaline release. This may be a non-specific effect. Nevertheless, an effect involving the parasympathetic nervous system is possible. This idea is supported by Results the fact that a parasympathetic innervation is lacking in the kidney, where AT2 receptor blockade was withElectrical nerve stimulation elicited noradrenaline out an effect. Acetylcholine is known to inhibit norrelease. Ang II (0.01-0.1 mM ) increased noradrenaline adrenaline release in the heart of animal models [6 ] , outflow by~80% in kidney and in heart atrium acting through muscarinic receptors on sympathetic (Figure 1) . EXP3174 (0.01 mmol/l ) shifted the concen-nerves. We have shown that Ang II increases acetyltration response curve for Ang II to the right (data choline release. We speculate that activation of AT1 not shown), whereas a 10 times greater concentration receptors enhances and activation of AT2 receptors 5. Rump LC, Schwertfeger E, Schaible U, Fraedrich G, Schollmeyer P. Beta 2-adrenergic receptor and angiotensin II receptor modulation of sympathetic neurotransmission in human
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